Fertility app aims to boost medication adherence and quality of life
NCT ID NCT07690969
First seen Jul 08, 2026 · Last updated Jul 31, 2026 · Updated 3 times
Summary
This study tests a mobile health app called OPUCARE designed to support women with infertility who are about to undergo egg retrieval. The app provides medication reminders, treatment information, side-effect tips, and motivational messages. Researchers want to see if using the app helps women take their medications more consistently and improves their quality of life and anxiety levels compared to standard clinic care alone.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- OPUCARE mobile health application
- What this could lead to
- If it works, this app could help women undergoing fertility treatment better manage their medications and reduce anxiety, potentially improving their overall experience and outcomes.
- What could go wrong
- This is a small, early-stage study with only 60 participants, so results may not apply widely. The app's benefits may be modest or not significantly better than standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Female participants aged 18 years and older * Diagnosed with primary infertility * Scheduled to undergo oocyte pick-up (OPU) for the first time * Newly starting medication treatment during the period before OPU * Own a smartphone and are able to use basic mobile applications * Willing to participate in the study and provide written informed consent Exclusion Criteria: * Diagnosis of secondary infertility * Presence of a serious chronic disease that may significantly affect medication adherence and/or quality of life * Presence of an active serious psychiatric disorder * Cognitive or physical limitation that prevents use of the mobile application
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Female İnfertility are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Medipol MEGA University Hospital
Istanbul, 34214, Turkey (Türkiye)